Profil bibliographique

Manish Kohli

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

537Publications signalées

17718Citations signalées

3Affiliations récentes

Institutions déclarées

Huntsman (United States)University of Utah Huntsman Cancer Institute

Domaines associés

Prostate Cancer Treatment and ResearchCancer, Lipids, and MetabolismProstate Cancer Diagnosis and TreatmentCancer Genomics and DiagnosticsRadiopharmaceutical Chemistry and Applications

Publications récentes

Accès ouvert 2026 articleOpenAlex

Clinico-genomic risk stratification for biomarker-enriched trial design in poor-prognosis metastatic castrate-resistant prostate cancer (mCRPC)

Manish Kohli, Liang Wang, Aik Choon Tan, Muhammad Zaki Fadlullah et autres

0 citationsThe Journal of Liquid Biopsy

Accès ouvert 2026 preprintOpenAlex

Dissecting Multi-Omics Data for Cancer Survival Risk Prediction Using Variational Autoencoders: Current Trends, Challenges, and Opportunities

Sarmistha Das, Manish Kohli, Shukurat Rahmon, Robert A. Franklin et autres

0 citationsPreprints.org

2026 conference-abstractOpenAlex

HSD86 FIRST-LINE SYSTEMIC TREATMENT PATTERNS IN METASTATIC UROTHELIAL CARCINOMA IN US COMMUNITY ONCOLOGY PRACTICES

D M Shah, Asit Paul, Deepak Kilari, Roby Thomas et autres

0 citationsValue in Health

2026 conference-abstractOpenAlex

Cost-effectiveness analysis of eight treatments for metastatic hormone-sensitive prostate cancer (mHSPC) stratified by homologous recombination repair (HRR) status.

Manish Kohli, Richard Nelson, Maura Dougherty, Rebekah Gutowski et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

Rad2Nivo: Phase IB study of radium-223 (Rad) with nivolumab (Nivo) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Georges Gebrael, Gabriela Fort, Umang Swami, Sumati Gupta et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

Final results of Alliance A031902: A phase III trial of enzalutamide plus rucaparib as first-line therapy in metastatic castration-resistant prostate cancer (CASPAR).

Charles J. Ryan, DW Hillman, Karla V. Ballman, Alan Tan et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 articleOpenAlex

Quantum Dot Encoding for In-Solution Single-Molecule Biomarker Counting in Metastatic Prostate Cancer

Chia-Wei Kuo, Siva Nalla, Suresh Sarkar, Wonseok Lee et autres

1 citationACS Nano

Accès ouvert 2026 articleOpenAlex

Clinico-genomic nomograms for estimation of survival risk in metastatic castrate-resistant prostate cancer

Manish Kohli, Anushka Shankar, Jennifer Lloyd, Liang Wang et autres

1 citationJNCI Cancer Spectrum

Accès ouvert 2026 conference-abstractOpenAlex

Real-world ARPI utilization patterns and outcomes in metastatic castration-sensitive prostate cancer.

Manish Kohli, Jonathan D. Tward, Deepak Kilari, Asit K. Paul et autres

0 citationsJournal of Clinical Oncology

2026 conference-abstractOpenAlex

Real-world time to next treatment in metastatic urothelial cancer patients: Enfortumab vedotin and pembrolizumab vs chemotherapy as first-line treatment.

Dhaval Shah, Deepak Kilari, Bogdana Schmidt, Alejandro Sanchez et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 articleOpenAlex

OPTIMAS: A phase II randomized, decentralized, de-escalation trial in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) achieving optimal PSA response.

Umang Swami, Carter Johnson, Yeonjung Jo, Kenneth Michael Boucher et autres

0 citationsJournal of Clinical Oncology

Accès ouvert 2026 conference-abstractOpenAlex

Cost effectiveness of eight first-line regimens in metastatic hormone-sensitive prostate cancer (mHSPC) including niraparib + abiraterone acetate/prednisone.

Minkyoung Yoo, Richard Nelson, Maura Dougherty, Haeseon Lee et autres

0 citationsJournal of Clinical Oncology

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Recherche à la demande dans Crossref et Europe PMC, sans clé ; OpenAlex reste optionnel. Aucun service payant requis, aucune réponse conservée. Sources et limites.